To identify variables associated with early nasal continuous positive airway pressure (ENCPAP) failure in preterm neonates less than 30 weeks gestational age. STUDY DESIGN: Multicenter prospective study including 131 preterm newborns, over a period of 2 years. Patients and respiratory variables were assessed using univariate analysis. RESULT: Variables associated with ENCPAP failure were: the need of resuscitation with a FiO 2 40.30; a CPAP pressure of 6.4 ± 1.2 cm H 2 O; the need of a FiO 2 of 0.40 in the first 4 h of life; male gender maintaining the need of a FiO 2 40.25 in the first 4 h of life; and respiratory distress syndrome with criteria for surfactant administration. CONCLUSION: The need for oxygen in resuscitation and maintained in first hours of life, male gender, a CPAP pressure over 5 cm H 2 O and surfactant need are predictors of ENCPAP failure in preterm neonates 26 to 30 weeks gestational age.
INTRODUCTION
There is a growing interest in non-invasive forms of respiratory support for respiratory failure in most preterm babies, in the belief that this will reduce the need for invasive mechanical ventilation and its associated complications. 1 Immediately after birth, the lungs of a very preterm infant are vulnerable to injury of inappropriate respiratory support during resuscitation. [2] [3] [4] [5] [6] [7] Initial observational studies 8, 9 and more recent randomized studies, 10, 11 comparing early nasal continuous positive airway pressure (ENCPAP), starting in the delivery room, to primary intubation and mechanical ventilation, showed that ENCPAP reduced the need for invasive ventilation and surfactant treatment. Although this exciting non-invasive approach, ENCPAP, has been increasingly used, it has also shown a significant rate of failure, mainly associated with lower gestational ages and birth weights, as well as with oxygenation parameters in the first hours of life. [12] [13] [14] A consequence of this failure is that preterm neonates will receive their first surfactant dose later than the 'optimal' time. Combining a non-invasive ventilation approach with a strategy for surfactant administration is important, but questions remain about the optimal timing, mode of delivery and the value of predictive tests for surfactant deficiency. 15 Our study was planned to identify the variables associated with ENCPAP failure in preterm neonates less than 30 weeks gestational age.
METHODS
Inborn preterm newborns less than 30 weeks gestational age (29 weeks and 6 days inclusive) started on ENCPAP in the delivery room, born between a 2-year period (January 2010 to December 2011) in six level III centers in the north of Portugal, were prospectively included in the study.
Exclusion criteria were: endotracheal intubation in the delivery room, major congenital anomalies, hydrops fetalis, fetal TORCH infection and anemia (hemoglobino13 g dl À 1 ). The study protocol has been approved by all centers institute's committee on human research. An informed consent form was signed by parents.
All the centers participating in this study use the same delivery room resuscitation practices, according to the guidelines of the Portuguese Society of Neonatology (available at www.lusoneonatologia.com). In the delivery room, vigorous preterm infants o30 weeks gestational age with adequate preductal saturation could be stabilized either with or without any positive pressure, and ENCPAP was started after arriving to the neonatal intensive care unit (NICU), in the first 30 min of life. Not vigorous preterm o30 weeks, showing spontaneous breathing were placed on ENCPAP using either mask and T-piece resuscitator with a pressure of 6 to 8 cm H 2 O (Neopuff; Fisher & Paykel, Auckland, New Zealand) or directly placed on InfantFlow nasal CPAP (Care Fusion, Yorba Linda, CA, USA) with nasal prongs or mask with a pressure of 5 to 7 cm H 2 O. Recommended starting FiO 2 is 0.30 to achieve a preductal pulse oxygen saturation of 87 to 94%, and gradually reduced to 0.21, if possible. Transport to the intensive care unit, for those successfully stabilized with ENCPAP, was performed with InfantFlow nasal CPAP connected to the transport incubator or with nasopharyngeal tube and a neonatal transport ventilator (Infant Star 100, Infrasonics, San Diego, CA, USA or MVP 10 Pediatric Respirator, Biomed devices, Guilford, CT, USA). Patients that failed stabilization with ENCPAP were intubated in the delivery room and started on mechanical ventilation, and consequently, excluded from the study.
After arriving to the NICU, patients were placed in prone position and started on caffeine, kept until 34 weeks of gestational age. Starting total fluid intake was 70 ml kg À 1 per day and increased daily, according to the hemodynamic status. Nasal CPAP (InfantFlow) was used with pressures of 5 to 6 cm H 2 O in most cases, but could be increased up to 7 to 8 in particular cases. Patients with apnoeas requiring stimulation were changed to nasal CPAP with synchronized pressure assistance (Infant Flow SiPAP, Viasys Health Care, Palm Spring, CA, USA). Patients requiring FiO 2 40.40 with respiratory distress and/or arterial PCO 2 465 mm Hg and pH o7.20 were intubated for exogenous surfactant administration (Poractant alfa). The administration of surfactant was using either the INSURE method or a short period of mechanical ventilation before extubation for nasal CPAP. INSURE was routinely performed after an intravenous bolus of morphine (0.1 mg kg À 1 ). Naloxone (0.1 mg kg À 1 , IV push) was used if needed, to reverse respiratory depression caused by morphine. ENCPAP failure was considered when patients needed invasive mechanical ventilation during the first 72 h of life. NCPAP was continued until the infant was stable with FiO 2 of 0.21, normal arterial blood gases and pH, and no or mild respiratory effort.
The following data were collected: demographics, antenatal steroids, pathology of gestation, route of delivery, rupture of membranes 424 h, 5 min Apgar score, NCPAP pressure and use of CPAP with synchronized pressure assistance, failure of ENCPAP and causes, weight at 72 h of life, exogenous surfactant use, complications with NCPAP use, oxygentherapy, overall neonatal morbidity, day of discharge or death, cause of death in the deceased neonates, and histological exam of the placenta and necropsy study of deceased patients.
Antenatal steroid regimen was performed with betamethasone (24 mg, divided into two doses given intramuscularly to the mother, 24 h apart). Ampicillin, penicillin or clindamycin were started after 12 h of membranes rupture. Preterms with prolonged rupture of membranes or whose mothers were under antibiotic treatment for any other reason (fever, bacteriuria, leukocytosis, vaginal exudate and other) were started on treatment with ampicillin plus gentamicin. Gestational age (in this study we considered the completed weeks) was assessed by post-menstrual age (women with regular menstrual cycles), ultrasound examination (when a discrepancy of two or more weeks existed between the age derived by menstrual dating and the age-derived sonographically, or in the absence of a menstrual date) 16 or the New Ballard Score (in the absence of obstetrical indexes). 17 Small for gestational age was defined as a birth weight below 10th centile of Fenton's fetal growth charts. 18 Respiratory distress syndrome (RDS) was made on a combination of clinical and radiographic features according to the criteria of RDS of the Vermont Oxford Network (VON), once our unit is a collaborative member. The VON criteria of RDS are: (1) PaO 2 o50 mm Hg in room air, central cyanosis in room air, a requirement for supplemental oxygen to maintain PaO 2 450 mm Hg or a requirement for supplemental oxygen to maintain a pulse oximeter saturation over 85% within the first 24 h of life; and (2) a chest radiograph consistent with RDS (reticulogranular appearance to lung fields with or without low lung volumes and air bronchograms) within the first 24 h of life. We used, for practical purposes, the classification from I to III (I, light; II, moderate; III, severe), according to the X-ray appearance ranging from a light reticulogranular with air bronchograms to white lungs, adapted from the classification of Couchard et al. 19 The diagnosis of bronchopulmonary dysplasia was made according to de NIH Consensus Definition of Bronchopulmonary Dysplasia. 20 Oxygen, in all centers, was used to maintain saturations given by pulse oximetry in the range of 88 to 94% for RDS and 90 to 95% for bronchopulmonary dysplasia. Histological chorioamnionitis was classified according to the method proposed by Blanc. 21 Proven neonatal sepsis was defined as any systemic bacterial or fungal infection documented by a positive blood culture. Hemodynamically significant patent ductus arteriosus was diagnosed on the basis of the echocardiographic findings. The first evaluation was usually performed between 24 and 72 h of life, with daily evaluation until closure of the ductus. The standard treatment was indomethacin. The criteria of Bell were used for the diagnosis and staging of necrotizing enterocolitis. 22 Staging of retinopathy of prematurity was done according to the international classification. 23, 24 Intraventricular hemorrhage was classified according to Papile. 25 Periventicular leukomalacia was classified according to de Vries and Rennie. 26 The statistical analysis was performed using SPSS (IBM, New York, USA) for Windows, version 16 
RESULTS
Out of 201 preterm neonates less than 30 weeks gestation, 131 (65.1%) were included in this study. ENCPAP failure (o72 h of life) occurred in 27 (20.6%) patients. Demographic data on the overall study group, and the subgroups of ENCPAP failure and ENCPAP success are reported in Table 1 . Data on pregnancy, delivery mode and delivery room management are summarized in Tables 2 and 3 . The main causes of ENCPAP failure were: RDS ¼ 14 (51.8%); apnoeas ¼ 5 (18.5%); instability after surfactant administration ¼ 2 (7.4%); symptomatic patent ductus arteriosus ¼ 2 (7.4%); pneumothorax ¼ 1 (3.7%); pneumonia/sepsis ¼ 1 (3.7%); atelectasis ¼ 1 (3.7%) and severe intra-ventricular hemorrhage ¼ 1 (3.7%). In the ENCPAP failure group, intubation was performed at a median (interquartile range) age of 4 (1 to 14) h of life. Characteristics of ENCPAP use and weight loss at 72 h of life are reported in Table 4 . The need for oxygentherapy, higher NCPAP pressures, combination of oxygen needs with male gender, RDS and rate of surfactant use were significantly associated to ENCPAP failure. The combined outcome of two apparently protective factors, female gender and histological chorioamnionitis was not associated to significant success of ENCPAP (59 (56.7%) vs 11 (40.7%), P ¼ 0.138) The neonatal morbidity and mortality are shown in Table 5 , and RDS was significantly associated to ENCPAP failure. Three neonates were deceased because of nosocomial sepsis.
DISCUSSION
Resuscitation of preterm infants at birth is, almost always, a matter of establishing effective ventilation. 27 Chest compressions and medications are very rarely needed. 27 The COIN-trial 28 showed that ENCPAP is feasible and was associated with a reduced need for oxygen at 28 days of life, but only a trend toward a reduction in death or bronchopulmonary dysplasia at 36 week's corrected age. Current research is challenging widely held views about neonatal resuscitation, and suggesting that a less aggressive, more gentle approach may be more beneficial and cause less lung injury.
With this prospective study, we tried to identify the variables associated with ENCPAP failure in preterm neonates less than 30 weeks gestational age. To date, a few studies were performed to look for predictive variables for ENCPAP failure in preterm infants. Ammari et al. 12 reported that CPAP failure was associated with lower gestational age, birth weight, need for positive pressure ventilation at delivery, alveolar-arterial oxygen tension gradient (A-a DO 2 ) 4180 mm Hg on the first arterial blood gas and severe RDS on the initial chest X-ray. Fuchs et al. 13 reported that medical history or initial blood gas values were poor predictors of ENCPAP failure, but surfactant administration at low thresholds of fraction of inspired oxygen (FiO 2 0.35 to 0.45 vs X0.6) would shorten the time of surfactant delivery without a relevant increase in intubation rate. De Jaegere et al., 14 in a retrospective study, found that birth weight o800 g and male gender combined with a fraction of inspired oxygen 40.25 at 1 and 2 h of age were significantly associated with ENCPAP failure.
In our study, we did not find a significant difference between birth weight or gestational age at birth in the preterm babies in both ENCPAP failure and ENCPAP success groups. This fact may study, 45% of infants less than 28 weeks gestation required intubation for resuscitation in the delivery room.
Other limitation of our study is the fact that nine patients in the ENCPAP failure group started nasal CPAP in the NICU (in the first 30 min of life) and not in the delivery room. Initiation of ENCPAP earlier could have yielded different results.
Although female gender was more prevalent in the ENCPAP success group, there was no statistically difference between genders and ENCPAP failure, unless the need for oxygentherapy was considered. Indeed, in the ENCPAP failure group, males significantly needed more oxygen (FiO 2 40.25) maintained for at least the first 4 h after birth. The need for a fraction of inspired oxygen of 0.40 in the first 4 h of life was associated to ENCPAP failure, independently of gender. The ENCPAP failure group also used significantly higher pressures on the CPAP, and this is in accordance to the higher rate of RDS and the occurrence of one pneumothorax.
Data on pregnancy and delivery route were not significantly different in both groups. Although histological chorioamnionitis was more prevalent in ENCPAP success group, suggesting a protective effect, this prevalence was not statistically significant. We assessed the combined outcome of two apparently protective factors, female gender and histological chorioamnionitis, but, once again, we found no statistical significance.
Regarding to the delivery room management data, the need for a fraction of inspired oxygen over 0.30 was significant for those that failed ENCPAP later in the NICU.
RDS and need for surfactant (one or two doses) was significantly higher in the ENCPAP failure group. We did not use surfactant in a prophylactic way once it has been shown, by the CURPAP Study Group, that its use is not superior to ENCAP and early selective surfactant in decreasing the need for mechanical ventilation and the incidence of the main morbidities of prematurity. 30 Symptoms of respiratory distress at birth in preterm infants may not be due to hyaline membrane disease, but to the effort to clear fluid from the lungs. Expectant management (without immediate intubation) has shown that some preterm infants can be treated with ENCPAP. Once the alveoli are aerated and the fluid is clearing, the work of breath is less and abnormal respiratory symptoms may diminish. ENCPAP aids lung expansion and fluid clearance and also allows time to differentiate between hyaline membrane disease and transition problems. With this thought in mind, of fluid handling by the preterm lung, we decided to assess the weight at 72 h of age, but we could not find a statistically difference between both the groups.
According to the results of our study, predictors of ENCPAP failure in preterm infants 26 to 30 weeks of gestational age are: (1) the need of resuscitation with a fraction of inspired oxygen 40.30; These findings may help clinicians in the decision to continue or end the provision of ENCPAP during the respiratory transition of preterm neonates of 26 to 30 weeks gestational age. 
